Catalyst Event
Innovent Biologics Inc (1801) · Other
From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)
5/8/2026, 12:00:00 AM
The NMPA is expected to approve the Mazdutide pen for type 2 diabetes on May 8, 2026; this core product approval's medium market impact is expected
Korean Translation
2026년 5월 8일 중국 NMPA의 마즈두타이드 펜 승인이 예상되며, 핵심 제품 승인의 중간 정도 시장 영향력이 예상됨
Related Recent Events
3SBio Inc (1530) · Earnings Release
First half 2026 earnings results are expected to be released around August 26, 2026, expected. High importance is estimated due to the significant impact of previous earnings growth on stock volatility.
8/26/2026, 12:00:00 AM
Cochlear Ltd (COH) · Earnings Release
Cochlear's full-year financial results for fiscal year 2026 are scheduled to be announced on August 18, 2026. Medium importance is estimated as annual earnings reports typically result in price movements exceeding 5%, scheduled.
8/18/2026, 12:00:00 AM
3SBio Inc (1530) · Other
The ex-dividend date for the final cash dividend of HKD 0.25 per share for the fiscal year 2025 is July 21, 2026, scheduled.
7/21/2026, 12:00:00 AM
Sino Biopharmaceutical Ltd (1177) · Other
The ex-dividend date for the proposed final dividend of HKD 0.05 per share is 2026-06-24, which is estimated to have a price impact of ≥1% scheduled.
6/24/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
Medtronic PLC (MDT) · Earnings Release
Medtronic to report Q4 and full fiscal year 2026 financial results, scheduled.
6/3/2026, 12:00:00 AM